Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy
Hepcidin is an iron metabolism inhibitor that increases with chronic inflammation. However, it is unclear whether hepcidin indicates acute inflammatory response in Kawasaki disease (KD), which is an acute systemic vasculitis. In this study, we examined the serum hepcidin levels before and after intr...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2021-12, Vol.40 (12), p.5019-5024 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5024 |
|---|---|
| container_issue | 12 |
| container_start_page | 5019 |
| container_title | Clinical rheumatology |
| container_volume | 40 |
| creator | Ishikawa, Takashi Wada, Yasuyuki Namba, Hiroyuki Kawai, Toshinao |
| description | Hepcidin is an iron metabolism inhibitor that increases with chronic inflammation. However, it is unclear whether hepcidin indicates acute inflammatory response in Kawasaki disease (KD), which is an acute systemic vasculitis. In this study, we examined the serum hepcidin levels before and after intravenous immunoglobulin (IVIG) therapy in responders and non-responders to IVIG. This was a pilot prospective observational study at a university hospital. All KD patients were initially administered 2 g/kg of IVIG as the first IVIG therapy (IVIG
1
) on day 4 to day 7 after onset. Non-responders to IVIG
1
were additionally treated with the second IVIG therapy (IVIG
2
) using 1 g/kg of IVIG. All KD patients were also treated with aspirin. We measured serum hepcidin levels before IVIG
1
, after IVIG
1
, and during the recovery period. Among the 31 KD patients, 21 patients and 5 patients improved after IVIG
1
(responders-1) and IVIG
2
(responders-2), respectively, but 5 patients did not improve after IVIG
2
(non-responders). Serum hepcidin levels before IVIG
1
were significantly higher in responders-2 (159.0 ng/mL) and non-responders (240.0 ng/mL), compared to responders-1 (103.0 ng/mL). Serum hepcidin levels after IVIG
1
were significantly higher in non-responders (163.0 ng/mL), compared to responders-1 (43.4 ng/mL) and responders-2 (54.6 ng/mL). Serum hepcidin levels of non-responders to IVIG were higher before IVIG and remained high after IVIG. Erythrocyte-related indexes, including hemoglobin, reticulocytes, iron, and ferritin before IVIG
1
, were not significantly different among the three groups. Serum hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG.
Key Points
• Hepcidin, an iron metabolism inhibitor in chronic inflammation, increases during the acute phase of Kawasaki disease.
• Hepcidin levels before IVIG of non-responders were higher than those of responders in Kawasaki disease.
• Hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG. |
| doi_str_mv | 10.1007/s10067-021-05822-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2543706589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2598302745</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-8708c6a8e5b6a30fbf7091748c2360de26d7683d7b1a97d67244305e9a3edbfc3</originalsourceid><addsrcrecordid>eNp9kU9rFjEQh4NY8LX1C3gKePGymn-7SbxJsVYseNFzmM3Ovk3dza5JtvLe-8EbXUHwIITJMDzPMPAj5CVnbzhj-m2utdMNE7xhrRGiUU_IgSupGmuVfUoOTGvWSG7NM_I85zvGmDCWH8jDNa4-DCHS-j7DT8jwPdAhZISM7-i2JjxuE5SwRNqfKPitYEXHCeZ5n1ZvrR3Gkukt3Id4pAlzyAWiR1qWCpQE9xiXLdMwz1tcjtPSb1MVyy0mWE8X5GyEKeOLP_85-Xb14evldXPz5eOny_c3jZetKI3RzPgODLZ9B5KN_aiZ5VoZL2THBhTdoDsjB91zsHrotFBKshYtSBz60ctz8nrfu6blx4a5uDlkj9MEEet1TrRKata1xlb01T_o3bKlWK-rlDWSCa3aSomd8mnJOeHo1hRmSCfHmfsVjNuDcTUY9zsYp6okdylXOB4x_V39H-sRP3yTZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598302745</pqid></control><display><type>article</type><title>Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy</title><source>Springer Nature - Complete Springer Journals</source><creator>Ishikawa, Takashi ; Wada, Yasuyuki ; Namba, Hiroyuki ; Kawai, Toshinao</creator><creatorcontrib>Ishikawa, Takashi ; Wada, Yasuyuki ; Namba, Hiroyuki ; Kawai, Toshinao</creatorcontrib><description>Hepcidin is an iron metabolism inhibitor that increases with chronic inflammation. However, it is unclear whether hepcidin indicates acute inflammatory response in Kawasaki disease (KD), which is an acute systemic vasculitis. In this study, we examined the serum hepcidin levels before and after intravenous immunoglobulin (IVIG) therapy in responders and non-responders to IVIG. This was a pilot prospective observational study at a university hospital. All KD patients were initially administered 2 g/kg of IVIG as the first IVIG therapy (IVIG
1
) on day 4 to day 7 after onset. Non-responders to IVIG
1
were additionally treated with the second IVIG therapy (IVIG
2
) using 1 g/kg of IVIG. All KD patients were also treated with aspirin. We measured serum hepcidin levels before IVIG
1
, after IVIG
1
, and during the recovery period. Among the 31 KD patients, 21 patients and 5 patients improved after IVIG
1
(responders-1) and IVIG
2
(responders-2), respectively, but 5 patients did not improve after IVIG
2
(non-responders). Serum hepcidin levels before IVIG
1
were significantly higher in responders-2 (159.0 ng/mL) and non-responders (240.0 ng/mL), compared to responders-1 (103.0 ng/mL). Serum hepcidin levels after IVIG
1
were significantly higher in non-responders (163.0 ng/mL), compared to responders-1 (43.4 ng/mL) and responders-2 (54.6 ng/mL). Serum hepcidin levels of non-responders to IVIG were higher before IVIG and remained high after IVIG. Erythrocyte-related indexes, including hemoglobin, reticulocytes, iron, and ferritin before IVIG
1
, were not significantly different among the three groups. Serum hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG.
Key Points
• Hepcidin, an iron metabolism inhibitor in chronic inflammation, increases during the acute phase of Kawasaki disease.
• Hepcidin levels before IVIG of non-responders were higher than those of responders in Kawasaki disease.
• Hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-021-05822-4</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aspirin ; Brief Report ; Ferritin ; Hemoglobin ; Hepcidin ; Immunoglobulins ; Inflammation ; Intravenous administration ; Iron ; Kawasaki disease ; Medicine ; Medicine & Public Health ; Metabolism ; Mucocutaneous lymph node syndrome ; Patients ; Reticulocytes ; Rheumatology ; Systemic vasculitis</subject><ispartof>Clinical rheumatology, 2021-12, Vol.40 (12), p.5019-5024</ispartof><rights>International League of Associations for Rheumatology (ILAR) 2021</rights><rights>International League of Associations for Rheumatology (ILAR) 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-8708c6a8e5b6a30fbf7091748c2360de26d7683d7b1a97d67244305e9a3edbfc3</citedby><cites>FETCH-LOGICAL-c352t-8708c6a8e5b6a30fbf7091748c2360de26d7683d7b1a97d67244305e9a3edbfc3</cites><orcidid>0000-0002-4152-9301</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-021-05822-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-021-05822-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids></links><search><creatorcontrib>Ishikawa, Takashi</creatorcontrib><creatorcontrib>Wada, Yasuyuki</creatorcontrib><creatorcontrib>Namba, Hiroyuki</creatorcontrib><creatorcontrib>Kawai, Toshinao</creatorcontrib><title>Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><description>Hepcidin is an iron metabolism inhibitor that increases with chronic inflammation. However, it is unclear whether hepcidin indicates acute inflammatory response in Kawasaki disease (KD), which is an acute systemic vasculitis. In this study, we examined the serum hepcidin levels before and after intravenous immunoglobulin (IVIG) therapy in responders and non-responders to IVIG. This was a pilot prospective observational study at a university hospital. All KD patients were initially administered 2 g/kg of IVIG as the first IVIG therapy (IVIG
1
) on day 4 to day 7 after onset. Non-responders to IVIG
1
were additionally treated with the second IVIG therapy (IVIG
2
) using 1 g/kg of IVIG. All KD patients were also treated with aspirin. We measured serum hepcidin levels before IVIG
1
, after IVIG
1
, and during the recovery period. Among the 31 KD patients, 21 patients and 5 patients improved after IVIG
1
(responders-1) and IVIG
2
(responders-2), respectively, but 5 patients did not improve after IVIG
2
(non-responders). Serum hepcidin levels before IVIG
1
were significantly higher in responders-2 (159.0 ng/mL) and non-responders (240.0 ng/mL), compared to responders-1 (103.0 ng/mL). Serum hepcidin levels after IVIG
1
were significantly higher in non-responders (163.0 ng/mL), compared to responders-1 (43.4 ng/mL) and responders-2 (54.6 ng/mL). Serum hepcidin levels of non-responders to IVIG were higher before IVIG and remained high after IVIG. Erythrocyte-related indexes, including hemoglobin, reticulocytes, iron, and ferritin before IVIG
1
, were not significantly different among the three groups. Serum hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG.
Key Points
• Hepcidin, an iron metabolism inhibitor in chronic inflammation, increases during the acute phase of Kawasaki disease.
• Hepcidin levels before IVIG of non-responders were higher than those of responders in Kawasaki disease.
• Hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG.</description><subject>Aspirin</subject><subject>Brief Report</subject><subject>Ferritin</subject><subject>Hemoglobin</subject><subject>Hepcidin</subject><subject>Immunoglobulins</subject><subject>Inflammation</subject><subject>Intravenous administration</subject><subject>Iron</subject><subject>Kawasaki disease</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Mucocutaneous lymph node syndrome</subject><subject>Patients</subject><subject>Reticulocytes</subject><subject>Rheumatology</subject><subject>Systemic vasculitis</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kU9rFjEQh4NY8LX1C3gKePGymn-7SbxJsVYseNFzmM3Ovk3dza5JtvLe-8EbXUHwIITJMDzPMPAj5CVnbzhj-m2utdMNE7xhrRGiUU_IgSupGmuVfUoOTGvWSG7NM_I85zvGmDCWH8jDNa4-DCHS-j7DT8jwPdAhZISM7-i2JjxuE5SwRNqfKPitYEXHCeZ5n1ZvrR3Gkukt3Id4pAlzyAWiR1qWCpQE9xiXLdMwz1tcjtPSb1MVyy0mWE8X5GyEKeOLP_85-Xb14evldXPz5eOny_c3jZetKI3RzPgODLZ9B5KN_aiZ5VoZL2THBhTdoDsjB91zsHrotFBKshYtSBz60ctz8nrfu6blx4a5uDlkj9MEEet1TrRKata1xlb01T_o3bKlWK-rlDWSCa3aSomd8mnJOeHo1hRmSCfHmfsVjNuDcTUY9zsYp6okdylXOB4x_V39H-sRP3yTZg</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Ishikawa, Takashi</creator><creator>Wada, Yasuyuki</creator><creator>Namba, Hiroyuki</creator><creator>Kawai, Toshinao</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4152-9301</orcidid></search><sort><creationdate>20211201</creationdate><title>Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy</title><author>Ishikawa, Takashi ; Wada, Yasuyuki ; Namba, Hiroyuki ; Kawai, Toshinao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-8708c6a8e5b6a30fbf7091748c2360de26d7683d7b1a97d67244305e9a3edbfc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aspirin</topic><topic>Brief Report</topic><topic>Ferritin</topic><topic>Hemoglobin</topic><topic>Hepcidin</topic><topic>Immunoglobulins</topic><topic>Inflammation</topic><topic>Intravenous administration</topic><topic>Iron</topic><topic>Kawasaki disease</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Mucocutaneous lymph node syndrome</topic><topic>Patients</topic><topic>Reticulocytes</topic><topic>Rheumatology</topic><topic>Systemic vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishikawa, Takashi</creatorcontrib><creatorcontrib>Wada, Yasuyuki</creatorcontrib><creatorcontrib>Namba, Hiroyuki</creatorcontrib><creatorcontrib>Kawai, Toshinao</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishikawa, Takashi</au><au>Wada, Yasuyuki</au><au>Namba, Hiroyuki</au><au>Kawai, Toshinao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><date>2021-12-01</date><risdate>2021</risdate><volume>40</volume><issue>12</issue><spage>5019</spage><epage>5024</epage><pages>5019-5024</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Hepcidin is an iron metabolism inhibitor that increases with chronic inflammation. However, it is unclear whether hepcidin indicates acute inflammatory response in Kawasaki disease (KD), which is an acute systemic vasculitis. In this study, we examined the serum hepcidin levels before and after intravenous immunoglobulin (IVIG) therapy in responders and non-responders to IVIG. This was a pilot prospective observational study at a university hospital. All KD patients were initially administered 2 g/kg of IVIG as the first IVIG therapy (IVIG
1
) on day 4 to day 7 after onset. Non-responders to IVIG
1
were additionally treated with the second IVIG therapy (IVIG
2
) using 1 g/kg of IVIG. All KD patients were also treated with aspirin. We measured serum hepcidin levels before IVIG
1
, after IVIG
1
, and during the recovery period. Among the 31 KD patients, 21 patients and 5 patients improved after IVIG
1
(responders-1) and IVIG
2
(responders-2), respectively, but 5 patients did not improve after IVIG
2
(non-responders). Serum hepcidin levels before IVIG
1
were significantly higher in responders-2 (159.0 ng/mL) and non-responders (240.0 ng/mL), compared to responders-1 (103.0 ng/mL). Serum hepcidin levels after IVIG
1
were significantly higher in non-responders (163.0 ng/mL), compared to responders-1 (43.4 ng/mL) and responders-2 (54.6 ng/mL). Serum hepcidin levels of non-responders to IVIG were higher before IVIG and remained high after IVIG. Erythrocyte-related indexes, including hemoglobin, reticulocytes, iron, and ferritin before IVIG
1
, were not significantly different among the three groups. Serum hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG.
Key Points
• Hepcidin, an iron metabolism inhibitor in chronic inflammation, increases during the acute phase of Kawasaki disease.
• Hepcidin levels before IVIG of non-responders were higher than those of responders in Kawasaki disease.
• Hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s10067-021-05822-4</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4152-9301</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2021-12, Vol.40 (12), p.5019-5024 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2543706589 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Aspirin Brief Report Ferritin Hemoglobin Hepcidin Immunoglobulins Inflammation Intravenous administration Iron Kawasaki disease Medicine Medicine & Public Health Metabolism Mucocutaneous lymph node syndrome Patients Reticulocytes Rheumatology Systemic vasculitis |
| title | Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A39%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepcidin%20in%20Kawasaki%20disease:%20upregulation%20by%20acute%20inflammation%20in%20patients%20having%20resistance%20to%20intravenous%20immunoglobulin%20therapy&rft.jtitle=Clinical%20rheumatology&rft.au=Ishikawa,%20Takashi&rft.date=2021-12-01&rft.volume=40&rft.issue=12&rft.spage=5019&rft.epage=5024&rft.pages=5019-5024&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-021-05822-4&rft_dat=%3Cproquest_cross%3E2598302745%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2598302745&rft_id=info:pmid/&rfr_iscdi=true |